Summary
Unable to evaluate alignment because the provided label excerpts do not include all required specific language (e.g., contraindications/warnings/administration/interaction details beyond CYP3A4 and grapefruit). Several claims in the response go beyond or are not explicitly supported by the supplied excerpts, but the audit cannot confirm support/contradiction reliably across all statements with the limited label text provided.
Category Scores
Accurate Statements
Lipitor (atorvastatin) belongs to a class of drugs called HMG-CoA reductase inhibitors.
Label 12.1: “LIPITOR is a selective, competitive inhibitor of HMG-CoA reductase.”
HMG-CoA reductase inhibitors work by blocking the production of cholesterol in the liver.
Label 12.1 and mechanism language provided: “selective, competitive inhibitor of HMG-CoA reductase.” (No liver-specific mechanism text was explicitly provided in the excerpt.)
Grapefruit juice contains components that inhibit CYP3A4 and can increase plasma concentrations of atorvastatin.
Label 7.2: “Contains one or more components that inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin…”
Patients should avoid excessive grapefruit juice consumption (>1.2 liters per day).
Label 7.2: “…especially with excessive grapefruit juice consumption (>1.2 liters per day).”
Rare cases of rhabdomyolysis with acute renal failure have been reported with LIPITOR.
Label 5.1: “Rare cases of rhabdomyolysis with acute renal failure… have been reported with LIPITOR…”
Unsupported Statements
By reducing cholesterol levels, Lipitor helps prevent the buildup of plaque in arteries.
The provided label excerpts include risk reduction outcomes (e.g., MI, stroke, revascularization) but do not explicitly state plaque buildup prevention.
Lipitor reduces the risk of heart disease and stroke.
The label excerpt supports reduction in myocardial infarction and stroke risk, but it does not use the phrase “heart disease.”
Grapefruit contains a compound called furanocoumarin.
Not supported by the provided label excerpts.
Grapefruit furanocoumarin includes bergamottin.
Not supported by the provided label excerpts.
Bergamottin inhibits the enzyme CYP3A4.
Not supported by the provided label excerpts.
CYP3A4 is responsible for metabolizing many medications, including Lipitor.
Label excerpt 7.2 supports CYP3A4 inhibition affecting atorvastatin concentrations, but the statement that CYP3A4 metabolizes many medications (and “including Lipitor”) is not explicitly provided in the supplied text.
Consumption of grapefruit inhibits CYP3A4.
Label supports that grapefruit juice contains components that inhibit CYP3A4 (7.2), but the claim is phrased generally without the label’s “components” language; still likely partially supported, but the label excerpt does not support the broader mechanistic phrasing as written.
Inhibiting CYP3A4 increases the levels of Lipitor in the bloodstream.
Label 7.2 supports increased plasma concentrations of atorvastatin, not explicitly “Lipitor in the bloodstream” wording.
Increased Lipitor levels can lead to potentially toxic effects.
Label excerpt does not explicitly connect grapefruit/CYP3A4-mediated concentration increases to “potentially toxic effects” as a general statement.
Mixing Lipitor and grapefruit increases the risk of muscle damage.
Label 5.1 discusses myopathy/rhabdomyolysis risk increased with certain interacting drugs, and label 7.2 discusses increased concentrations with grapefruit; the label excerpts provided do not explicitly state grapefruit increases muscle damage risk.
Elevated levels of Lipitor can cause muscle damage with pain, weakness, and fatigue.
Label excerpts do not provide this symptom constellation linked to elevated levels.
Increased Lipitor levels can cause liver damage.
Label excerpt 5.2 discusses liver enzyme elevations and contraindications/monitoring, but does not explicitly state that increased levels from grapefruit cause “liver damage.”
Grapefruit's inhibition of CYP3A4 can potentially cause life-threatening conditions.
Not explicitly supported by the supplied grapefruit interaction text.
Grapefruit's effects on CYP3A4 can lead to interactions with other medications.
Label does not discuss grapefruit interaction breadth in the provided excerpt beyond atorvastatin.
Grapefruit interactions with CYP3A4 may involve blood thinners.
Not supported by the provided label excerpts.
Grapefruit interactions with CYP3A4 may involve immunosuppressants.
Not supported by the provided label excerpts.
Grapefruit interactions with CYP3A4 may involve certain antibiotics.
Not supported by the provided label excerpts.
The interaction between grapefruit juice and atorvastatin is due to inhibition of CYP3A4 by bergamottin.
The bergamottin/furanocoumarin mechanism is not supported by the provided label excerpts; only “components” inhibiting CYP3A4 is provided.
Increased atorvastatin levels can cause adverse effects.
Label supports adverse reactions with atorvastatin, but the supplied excerpts do not explicitly tie “increased levels” from grapefruit to adverse effects.
Grapefruit juice can significantly increase the levels of atorvastatin in the bloodstream.
Label 7.2 states it can increase plasma concentrations, especially with excessive consumption, but does not explicitly say “significantly” or “bloodstream.”
Increasing atorvastatin levels increases the risk of adverse effects.
Not explicitly stated in the provided excerpts.
Patients should avoid consuming grapefruit juice while taking Lipitor.
Label 7.2 is framed around components inhibiting CYP3A4 and “especially with excessive grapefruit juice consumption (>1.2 liters per day).” It does not state complete avoidance in the provided excerpts.
Patients should avoid consuming grapefruit juice or products containing bergamottin (including marmalade) while taking Lipitor.
Not supported because bergamottin and marmalade are not addressed in the provided label excerpts.
Patients should consult their healthcare provider before taking Lipitor.
Label excerpts provided do not include this counseling instruction.
Patients should work with their healthcare provider to monitor their medication levels.
The provided label excerpts discuss lab monitoring (e.g., liver function tests) but do not mention monitoring medication levels of atorvastatin for the grapefruit interaction.
Patients should adjust their Lipitor dose as needed based on monitoring their medication levels.
No such guidance is present in the supplied label excerpts.
The grapefruit juice–Lipitor interaction can occur within 30 minutes to 2 hours after consuming grapefruit juice.
Not supported by the provided label excerpts.
Symptoms of a grapefruit-Lipitor interaction can include muscle pain.
Label excerpt 5.1 discusses myopathy/rhabdomyolysis risk; it does not list “muscle pain” as specific grapefruit-interaction symptoms.
Symptoms of a grapefruit-Lipitor interaction can include weakness.
Not supported by provided label excerpts.
Symptoms of a grapefruit-Lipitor interaction can include fatigue.
Not supported by provided label excerpts.
Symptoms of a grapefruit-Lipitor interaction can include liver damage.
Not supported; label 5.2 mentions liver enzyme elevations and monitoring, not symptom lists for grapefruit interaction.
If patients have already consumed grapefruit juice, they should monitor their medication levels.
No such instruction is present in the provided label excerpts.
If patients have already consumed grapefruit juice, they should consult their healthcare provider.
Not supported by provided label excerpts.
Contradictions
Important Omissions
The label excerpt does not support blanket avoidance of grapefruit juice; it emphasizes increased plasma concentrations especially with excessive grapefruit juice consumption (>1.2 liters/day). The response’s blanket avoidance wording omits this threshold nuance.
Importance:
Moderate
The response discusses monitoring/adjusting atorvastatin based on medication levels, but the provided label excerpts instead include liver function test monitoring prior to and after initiation (and discuss clinical monitoring for muscle issues). Medication-level monitoring is not shown in the excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Several statements about grapefruit (e.g., bergamottin/marmalade, time window of interaction, symptom lists, and blanket avoidance/monitoring medication levels) are not supported by the supplied prescribing information excerpts. These could lead to incorrect counseling or inappropriate monitoring expectations.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple grapefruit-mechanism and patient-management claims (bergamottin/furanocoumarins, marmalade, timing, symptom constellation, monitoring medication levels, blanket avoidance) are not supported by the provided label excerpts.
Suggested Improvement
Limit grapefruit interaction discussion to label-supported language: components inhibit CYP3A4 and increase plasma atorvastatin concentrations, especially with excessive grapefruit juice consumption (>1.2 liters/day). Remove unsupported claims about bergamottin/furanocoumarins, marmalade, specific time-to-interaction window, symptom lists, and medication-level monitoring/dose adjustment based on those levels.